Anxiety, pain, and nausea during the treatment of standard‐risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group

Abstract

BACKGROUND This prospective study describes the procedure-related anxiety, treatment-related anxiety, pain, and nausea experienced by children with standard-risk acute lymphoblastic leukemia (ALL) during the first year of treatment. METHODS This study was undertaken at 31 Children’s Oncology Group (COG) sites. Eligible children who were 2 to 9.99 years old were enrolled in a COG trial for patients with newly diagnosed standard-risk ALL from 2005 to 2009. Parents completed a demographic survey at the baseline and the Pediatric Quality of Life Inventory 3.0 Cancer Module (proxy version) and the General Functioning Scale of the Family Assessment Device 1, 6, and 12 months after the diagnosis. The association between patient-related (age, sex, ethnicity, and treatment), parent-related (marital status and education), and family-related factors (functioning, income, and size) and symptom scores was evaluated. RESULTS The mean scores for procedure-related anxiety, treatment-related anxiety, and pain improved during the first year of treatment (P < .0389). The mean nausea score was poorer 6 months after the diagnosis in comparison with the other assessments (P = .0085). A younger age at diagnosis was associated with significantly worse procedure-related anxiety (P = .004). An older age (P = .0002) and assignment to the intensified consolidation study arm (P = .02) were associated with significantly worse nausea. CONCLUSIONS Children with ALL experienced decreasing treatment-related anxiety, procedure-related anxiety, and pain during the first year of treatment. In comparison with scores at 1 and 12 months, nausea was worse 6 months after the diagnosis. Minimization of procedure-related anxiety in younger children and improved nausea control in older children and those receiving more intensified treatment should be prioritized.

Comparison of hypersensitivity rates to intravenous and intramuscular PEG‐asparaginase in children with acute lymphoblastic leukemia: A meta‐analysis and systematic review

“…The majority of relatively recent published RCTs conducted in Europe and North America administered IM PEG‐ASP . A recently (2015) published RCT (DFC 005‐01) by Place et al .…”

Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer

“…Vinblastine and vincristine were the first vinca alkaloids approved for clinical use as anticancer agents. Vincristine is approved and used for induction therapy in childhood ALL (77). Several studies in pediatric patients show that vincristine has a sensitizing effect with cytotoxic chemotherapy (78-80).…”

High prevalence of parent‐reported sleep problems in pediatric patients with acute lymphoblastic leukemia after induction therapy

“…Pediatric patients with cancer are prone to sleep problems due to physical (i.e., tumor location, treatment, and toxicity) as well as psychosocial factors (i.e., anxiety and fatigue) . Acute lymphoblastic leukemia (ALL) is the most common type of childhood cancer and it requires an intensive treatment regimen of frequent chemotherapy administrations over the course of 2‐3 years .…”